AFP and hepatocellular carcinoma: Serum miR‐363‐5p and PIVKA‐II levels were significantly higher in AFP‐HCC (miR‐363‐5p: 3.7 ± 1.0; PIVKA‐II: 42.0 ± 9.2 mAU/mL) patients than in cirrhosis (miR‐363‐5p: 2.3 ± 0.7; PIVKA‐II: 27.4 ± 5.7 mAU/mL) and controls (miR‐363‐5p: 1.7 ± 0.4; PIVKA‐II: 15.8 ± 4.6 mAU/mL), while serum miR‐363‐5p and PIVKA‐II levels were significantly higher in patients with cirrhosis than in controls (P < .05, Figure 2C,E).